ARAY Accuray Cyberknife Robotic RadioSurgery | Stock Discussion Forums

SiliconInvestor

register

Sponsor

register

Biotech / Medical | ARAY Accuray Cyberknife Robotic RadioSurgery

From: Savant	5/17/2012 11:13:18 AM
	of 70

Accuray Appoints Richard Pettingill, LFACHE to Board of Directors SUNNYVALE, Calif., May 17, 2012 /PRNewswire via COMTEX/ -- Accuray Incorporated (ARAY), the premier radiation oncology company, announced today the appointment of Richard Pettingill, LFACHE as a member of the company's Board of Directors effective May 11, 2012. Richard Pettingill's career as a healthcare executive spans four decades and includes leadership positions in a variety of prominent organizations. Most recently, Pettingill, who is a Lifetime Fellow of the American College of Healthcare Executives (LFACHE), served as the President and Chief Executive Officer of Allina Health System, Minnesota's and western Wisconsin's largest healthcare organization. Under Pettingill's leadership, Allina Health System emerged as one of the country's leading integrated care delivery organizations - increasing revenues by more than 50 percent and growing its market share to more than 30 percent. Additionally, under Pettingill's leadership, Allina was the recipient of the Health Information Management System Society 2007 Davies Award for the innovative implementation of a comprehensive electronic medical record system. "Richard Pettingill is a proven healthcare leader and makes a great addition to our Board of Directors," said Euan S. Thomson, Ph.D., president and CEO of Accuray. "Pettingill's in-depth, long-standing knowledge of the healthcare industry from the provider perspective will be an asset as Accuray navigates the changing healthcare landscape." After his tenure at Allina Health System, Pettingill served as an Advanced Leadership Fellow at Harvard University in 2010. Prior to joining Allina Health System, he served as the President and Chief Executive Officer, California Division, Kaiser Foundation Health Plan and Hospitals where he oversaw the nearly 6 million-member health plan throughout California, as well as President and Chief Executive Office of Camino Healthcare. Pettingill currently serves on the boards of publicly traded companies Tenet Healthcare Corporation and MAKO Surgical Corp. "I am impressed with Accuray's innovative approach to radiation oncology and pleased to be joining its Board of Directors," said Richard Pettingill. "I know first-hand the difficult positions healthcare organizations face today with ever-increasing pressure to control costs while improving patient care experience. Accuray's CyberKnife and TomoTherapy Systems are advanced cancer treatments that use innovative technology to improve the efficiency and effectiveness of clinical care." About AccurayAccuray Incorporated (ARAY), based in Sunnyvale, Calif., is the premier radiation oncology company that develops, manufactures and sells personalized innovative treatment solutions that set the standard of care, with the aim of helping patients live longer, better lives. The Company's leading edge technologies - the CyberKnife and TomoTherapy Systems - are designed to deliver radiosurgery, stereotactic body radiation therapy, intensity modulated radiation therapy, image guided radiation therapy, and adaptive radiation therapy. To date, 635 systems have been installed in leading hospitals around the world. For more information, please visit accuray.com.

Share	Recommend \| Keep \| Reply \| Mark as Last Read

From: Savant	6/7/2012 9:14:33 AM
	of 70

CyberKnife? Prostate SBRT Outcomes and Quality of Life Data Presented at American Urological Association Meeting Long Term Outcomes for Intermediate-Risk Prostate Cancer Patients SUNNYVALE, Calif., June 7, 2012 /PRNewswire via COMTEX/ -- SUNNYVALE, Calif., June 7, 2012 /PRNewswire/-- Accuray Incorporated (ARAY), the premier radiation oncology company, announced today that outcome data on intermediate risk prostate cancer patients treated with CyberKnife? Prostate SBRT was presented at the American Urological Association Meeting (AUA) 2012 held in Atlanta, Ga. The prospective monotherapy study, titled, "Four Year Outcomes and Quality of Life Following Stereotactic Body Radiation Therapy: A Rapid, Non-Invasive Alternative for the Treatment of Intermediate-Risk Organ Confined Prostate Cancer," expands upon prior studies to further evaluate the long term efficacy and quality of life outcomes from treatment with CyberKnife stereotactic body radiation therapy (SBRT) for intermediate-risk prostate cancer patients. The study found a 91 percent biochemical control rate at four-years, which is comparable to both surgical and non-surgical treatments for intermediate risk prostate cancer patients, while demonstrating similar to improved toxicity outcomes. The study consisted of 81 intermediate-risk organ confined prostate patients treated by Dr. Alan Katz at Winthrop University Hospital with a median follow-up of four years including 24 patients with a minimum of five years follow up. This study showcases the long term published data on the use of the non-invasive CyberKnife SBRT five day course of treatment for intermediate-risk prostate cancer. Most notably the study found a four-year relapse-free survival rate of 91 percent. Patients experienced mild toxicity with minimal impact on quality of life and immediate to rapid return to normal activity. These results further support the value of CyberKnife prostate SBRT to achieve high rates of long term disease control while sparing healthy tissue and critical nearby structures, thereby minimizing undesirable side effects typically associated with other treatment modalities and preserving patients' quality of life. "CyberKnife prostate SBRT offers patients a short five-day, non-invasive treatment for organ confined prostate cancer," said Alan Katz, M.D., author of the study, currently a radiation oncologist at Flushing Radiation Oncology. "Based on our study results, patients with intermediate-risk prostate cancer have an option for a less invasive alternative to invasive surgery or six to eight weeks of conventionally fractionated radiation therapy, that effectively and efficiently treats their cancer, while preserving their overall quality of life." "This study represents positive long term outcomes of CyberKnife SBRT for intermediate-risk prostate patients, further supporting the value of this patient centric technique," said Omar Dawood, M.D., M.P.H., senior vice president of global medical affairs for Accuray. "These results add to the rapidly maturing strong foundation of published clinical evidence for CyberKnife prostate SBRT and further support the need to create head to head evidence to compare outcomes of this treatment with surgery and conventionally fractionated radiation treatments as is underway in the recently launched PACE study. We look forward to the outcomes of the PACE study, which aims to build upon these results and further support CyberKnife SBRT as a potential gold standard for the treatment for patients with organ confined prostate cancer." About AccurayAccuray Incorporated (ARAY), based in Sunnyvale, Calif., is the premier radiation oncology company that develops, manufactures and sells personalized innovative treatment solutions that set the standard of care, with the aim of helping patients live longer, better lives. The Company's leading edge technologies - the CyberKnife and TomoTherapy Systems - are designed to deliver radiosurgery, stereotactic body radiation therapy, intensity modulated radiation therapy, image guided radiation therapy, and adaptive radiation therapy. To date 635 systems have been installed in leading hospitals around the world. For more information, please visit accuray.com.

Share	Recommend \| Keep \| Reply \| Mark as Last Read

From: Savant	6/21/2012 9:43:34 AM
	of 70

One Year After TomoTherapy Acquisition, Accuray on Track to Meet or Exceed Integration Success Metrics And Expecting Near-term Return to Profitability CFO Presents Strategy to Deliver Growth and Vision for Future at Wells Fargo Healthcare Conference SUNNYVALE, Calif., June 21, 2012 /PRNewswire via COMTEX/ -- Accuray Incorporated (ARAY), the premier radiation oncology company, announced today the company's successes since its acquisition of TomoTherapy Incorporated one year ago and its vision for growth and profitability in the future, as part of a presentation by the company's chief financial officer Derek Bertocci at the Wells Fargo Healthcare Conference in Boston. As part of Accuray's transformative acquisition of TomoTherapy Incorporated on June 10, 2011, the company set forth success metrics. Through the first three quarters of FY2012, Accuray has consistently met or exceeded these goals. In addition to reiterating the company's plans to return to profitability by the end of fiscal year 2013, which ends June 30, 2013, Accuray provided additional milestones for its fiscal year 2013. These included enhanced revenue growth, beyond the maintained or modestly increased revenue the company committed to for fiscal 2012. Specific guidance for fiscal year 2013 will be announced during Accuray's earnings call for the results for 4th quarter of fiscal 2012, but the company intends to focus on maximizing product sales through continued product innovation and market penetration. Accuray also anticipates further service gross margin improvements reaching 20-22 percent for the full fiscal year 2013, which is higher than originally announced. This continues the significant achievement of three consecutive quarters of strong service gross margin improvements during fiscal 2012, climbing to 16.1 percent in Q3 of fiscal 2012, surpassing the company's original goal of 10 percent by the end of fiscal 2012. Service gross margin improvements stemmed primarily from improvement in the reliability of TomoTherapy? Systems, which has enhanced customer confidence and helped drive system sales. "At the one year anniversary of Accuray's acquisition of TomoTherapy Incorporated, we look back with pride on what we've accomplished to date, but most importantly reaffirm our commitment not only to achieving, but surpassing, our integration and growth goals," said Derek Bertocci, senior vice president, chief financial officer of Accuray. "We are realizing the strategic benefits we outlined when we announced the acquisition of TomoTherapy Incorporated through installed base expansion, revenue growth and improvement of service gross margins. The dramatic progress we've made means a lot of forward momentum as we start into our next fiscal year and work to return to profitability." Customers continue to recognize the value of Accuray's technologies - the CyberKnife? and TomoTherapy Systems - which are not only well differentiated but also best-in-class at delivering stereotactic radiosurgery/stereotactic body radiation therapy and image guided-intensity modulated radiation therapy. While cross selling multiple products to customers and the associated revenue synergies remain a significant future benefit of the acquisition, the majority of Accuray's growth continues to come from taking market share from its competitors, with 90 percent of the company's more than 600 units installed in rooms previously occupied by competitive products or newly constructed vaults. Therefore, unlike its competitors, the majority of installations for Accuray are to new customers that grow the company's market position and fuel the growth of its installed base, and in turn grow the company's service business. In order to maintain the company's strong innovation lead and accelerate both products, Accuray continues to invest heavily in R&D. Enabled by the acquisition of TomoTherapy, Accuray increased its R&D spend by 23 percent for the first three quarters of FY2012 from the spend by both companies during the same period in fiscal year 2011. Accuray expects to see operating expense benefits as a result of the company's increased scale and intends to reduce operating expenses to approximately 45 percent or less of revenues by the end of fiscal 2013. About AccurayAccuray Incorporated (ARAY), based in Sunnyvale, Calif., is the premier radiation oncology company that develops, manufactures and sells personalized innovative treatment solutions that set the standard of care, with the aim of helping patients live longer, better lives. The Company's leading edge technologies - the CyberKnife and TomoTherapy Systems - are designed to deliver radiosurgery, stereotactic body radiation therapy, intensity modulated radiation therapy, image guided radiation therapy, and adaptive radiation therapy. As of March 31, 2012, 635 systems have been installed in leading hospitals around the world. For more information, please visit accuray.com. Safe Harbor Statement Statements made in this press release that are not statements of historical fact are forward-looking statements and are subject to the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements in this press release relate, but are not limited, to revenue growth, service gross margin & reliability improvements, market penetration, installed base expansion, acquisition revenue synergies, market share gains, investment in R&D, and reduction in operating expenses. Forward-looking statements are subject to risks and uncertainties that could cause actual results to differ materially from expectations, including risks detailed from time to time under the heading "Risk Factors" in the Company's report on Form 10-K for fiscal year 2011, and its reports on Form 10-Q for the first, second and third quarters of fiscal 2012. Forward-looking statements speak only as of the date the statements are made and are based on information available to the Company at the time those statements are made and/or management's good faith belief as of that time with respect to future events. The Company assumes no obligation to update forward-looking statements to reflect actual performance or results, changes in assumptions or changes in other factors affecting forward-looking information, except to the extent required by applicable securities laws. Accordingly, investors should not place undue reliance on any forward-looking statements.

Share	Recommend \| Keep \| Reply \| Mark as Last Read

From: Savant	6/21/2012 9:47:44 AM
	of 70

Accuray Rolls Out Comprehensive Customer Service Program in Japan Company Strengthens its Commitment to the Japanese Market and to Supporting the Growth of the TomoTherapy? System Worldwide SUNNYVALE, Calif., June 20, 2012 /PRNewswire via COMTEX/ -- Accuray Incorporated (ARAY), the premier radiation oncology company, announced today the extension of its industry-leading Emerald Service Program for the TomoTherapy? System, which provides equipment protection and product updates that improve clinical uptime and enhance technology utilization, to customers throughout Japan. As part of its ongoing commitment to strengthening customer service globally, Accuray will now interact directly with TomoTherapy customers in Japan to provide Accuray's higher level service programs in the Japanese radiation oncology market. "We are dedicated to helping advance radiation oncology treatment in Japan and this is a significant move toward ensuring that our current and future customers throughout the country benefit from the highest quality customer service," said Euan S. Thomson, Ph.D., president and chief executive officer of Accuray. "We have seen clear traction for both the TomoTherapy and CyberKnife Systems in Japan and believe that by managing the service program directly, we will be able to increase touch points with our customers, hear about their needs first hand and reaffirm their confidence in our products." Japan is a global leader in the adoption of innovative medical technology and an important market for Accuray. The TomoTherapy System received Shonin approval from the Japanese Ministry of Health, Labor and Welfare (MHLW) in December 2004, and the first TomoTherapy System was installed in 2005. Both Accuray systems have gained widespread acceptance and presently there are 26 TomoTherapy Systems and 25 CyberKnife? Robotic Radiosurgery Systems in use in Japan. Previously, Hitachi Medical Corporation provided service and support for TomoTherapy customers in Japan. With the roll out of the Emerald Service Program in Japan, Hitachi Medical Corporation will transfer the regulatory approval and service business to Accuray. The move to take service in house demonstrates Accuray's continued commitment to delivering superior service for TomoTherapy customers and provides new opportunities for growth and further market penetration for both the CyberKnife and TomoTherapy Systems in Japan. Accuray forecasts that the transfer of the service business from Hitachi Medical Corporation to Accuray will drive an increase in service revenue with expected revenue of $5 to 5.5 million dollars over one year. Accuray and Hitachi Medical Corporation will continue to partner on sales and distribution, enabling Accuray to benefit from Hitachi Medical Corporation's deep territory penetration in the Japan's radiation oncology market. Accuray expects the relationship to also provide opportunities for future growth of the TomoTherapy business globally. The Emerald Service Program combines best-in-class product service offerings with guaranteed uptime for unparalleled reliability and customer satisfaction. The Emerald Service Program was extended to the TomoTherapy System in the United States in 2011 and the program is now available to customers in Japan.

Share	Recommend \| Keep \| Reply \| Mark as Last Read

From: Savant	6/26/2012 11:13:38 AM
	of 70

Accuray and Erasmus Medical Center Sign Master Research and Collaboration Agreement Partnership Creates Strategic Alliance for Advancement of Research in Radiation Oncology in the Netherlands SUNNYVALE, Calif., June 26, 2012 /PRNewswire via COMTEX/ -- Accuray Incorporated (ARAY), the premier radiation oncology company, announced today the signing of a multi-year master research and collaboration agreement with Erasmus Medical Center (MC), a leading research center in Rotterdam, the Netherlands and the largest of the eight university medical centers in the country. Accuray and Erasmus MC will partner on cutting-edge research in radiation oncology with the goal of advancing treatment technology and providing healthcare professionals with the most effective tools for patient care. "Erasmus MC has a long history of collaborating with Accuray and we are pleased to continue our partnership to advance radiation oncology," said Professor Peter C. Levendag, M.D., Ph.D., Chairman of the Radiation Oncology Department at Erasmus MC. "Our Center's extensive technical research and clinical experience with the CyberKnife System has helped us see and understand the many benefits that radiosurgery offers to cancer patients. We are pleased to reaffirm our commitment to working together to further validate the science of radiosurgery and clinical applications of the CyberKnife System." Accuray has been working together with Erasmus MC on research initiatives since the Center installed its first CyberKnife? Robotic Radiosurgery System in 2004, making them the fourth site in the Europe India Middle East and Africa (EIMEA) region to install a CyberKnife System at that time. To date, Erasmus MC has treated more than 1,000 patients with the CyberKnife System, performed a substantial amount of clinical research on the use of the CyberKnife System, and authored more than 20 technical and clinical publications in peer-reviewed journals and several book chapters. The Center has used novel research methods to evaluate the performance of the CyberKnife System, including an assessment of the impact of intra-fraction patient motion on clinical tracking accuracy, clinical tracking accuracy of lung treatments using the Synchrony? Respiratory Tracking System, dose calculation accuracy assessments, and methods for reducing treatment time. Currently, the Center is evaluating hypothetical path sets and assessing the InTempo(TM) Adaptive Imaging System, which enhances the CyberKnife System's ability to continually track and correct for motion of the prostate during treatment. "As one of the world's foremost academic oncology research centers, Erasmus MC is an important partner for us in advancing the use of the CyberKnife System," said Euan S. Thomson, Ph.D., Accuray president and chief executive officer. "Our collaboration will support the growing body of clinical evidence demonstrating the efficacy and benefits of the CyberKnife System and help us further expand, refine and customize cancer patient treatment. With the support of partners like Erasmus MC, Accuray is poised to lead the charge toward truly personalized radiation oncology." In the last quarter, Accuray announced two additional research and collaboration agreements including a multi-year master research and collaboration agreement with the University of Heidelberg and the German Cancer Research Center (Deutsches Krebsforschungszentrum, DKFZ), both luminary research institutions located in Heidelberg, Germany. About Erasmus MCErasmus MC is the largest and most authoritative scientific University Medical Center in the Netherlands. Almost 13,000 staff members work within the core tasks of patient care, education, and scientific research on the continuous improvement and enforcement of individual patient care and social healthcare. They develop high-level knowledge, pass this on to future professionals, and apply it in everyday patient care. Over the next five years, Erasmus MC wants to grow into one of the best medical institutes in the world. Erasmus MC is part of the Dutch Federation of University Medical Centers (NFU): nfu.nl. About AccurayAccuray Incorporated (ARAY), based in Sunnyvale, Calif., is the premier radiation oncology company that develops, manufactures and sells personalized innovative treatment solutions that set the standard of care, with the aim of helping patients live longer, better lives. The Company's leading edge technologies - the CyberKnife and TomoTherapy Systems - are designed to deliver radiosurgery, stereotactic body radiation therapy, intensity modulated radiation therapy, image guided radiation therapy, and adaptive radiation therapy. To date 635 systems have been installed in leading hospitals around the world. For more information, please visit accuray.com.

Share	Recommend \| Keep \| Reply \| Mark as Last Read

From: Savant	6/27/2012 12:05:35 PM
	of 70

Accuray Announces Installation of TomoTherapy? System at University of California, San Francisco Image-Guided, Intensity Modulated Radiation Therapy Added to UCSF's Suite of Treatment Options for Cancer Patients SUNNYVALE, Calif., June 27, 2012 /PRNewswire via COMTEX/ -- Accuray Incorporated (ARAY), the premier radiation oncology company, announced today that doctors at the University of California, San Francisco (UCSF) Helen Diller Family Comprehensive Cancer Center in San Francisco, Calif. are now treating cancer patients with the TomoTherapy? System, the only radiation therapy system specifically designed for integrated, daily, 3D image-guided, intensity modulated radiation therapy (IG-IMRT). The TomoTherapy System, which stands out as one of the most advanced and comprehensive radiation therapy technologies available, is capable of treating a broad range of tumors--from the most common to the most complex--with speed and precision while reducing radiation exposure to surrounding healthy tissue. The TomoTherapy System will help clinicians at UCSF to treat a broader range of tumors as well as personalize and expand radiation treatment options available to cancer patients "At UCSF, we are dedicated to offering the most advanced cancer treatment options available in order to provide accurate and highly individualized care for each patient," said Mack Roach, III, Professor Radiation Oncology and Urology, Chair Radiation Oncology at UCSF Helen Diller Family Comprehensive Cancer Center. "Having a dedicated system built from the ground up to deliver IMRT treatments is a valuable addition to our suite of cancer care technologies." UCSF installed its TomoTherapy System in May 2012 to replace a standard linear accelerator and to date has treated malignant tumors in the prostate, rectum, bladder and gynecological treatments. In addition to its TomoTherapy System, the Center offers the CyberKnife? Robotic Radiosurgery System which is also manufactured by Accuray, as well as a full brachytherapy program, a proton beam system and other stereotactic body radiation therapy and radiosurgery systems to ensure each patient has access to the best treatment option for their unique case. The TomoTherapy System utilizes daily computed tomography (CT) imaging to identify the exact position of the tumor on each day of treatment, enabling clinicians to customize treatment for each patient, minimize radiation exposure to healthy tissue and critical structures and reduce side effects. Unlike conventional systems, which allow radiation to be delivered from only a few directions, the TomoTherapy System rotates as the patient moves through the system resulting in treatments that can be delivered continuously to the tumor from hundreds of angles. More beam directions give physicians more control in how the treatment is delivered--and more assurance that the dose will be confined to the tumor, reducing the risk of short- and long-term side effects. About AccurayAccuray Incorporated (ARAY), based in Sunnyvale, Calif., is the premier radiation oncology company that develops, manufactures and sells personalized innovative treatment solutions that set the standard of care, with the aim of helping patients live longer, better lives. The Company's leading edge technologies - the CyberKnife and TomoTherapy Systems - are designed to deliver radiosurgery, stereotactic body radiation therapy, intensity modulated radiation therapy, image guided radiation therapy, and adaptive radiation therapy. To date 635 systems have been installed in leading hospitals around the world. For more information, please visit accuray.com.

Share	Recommend \| Keep \| Reply \| Mark as Last Read

From: Savant	7/16/2012 7:39:12 PM
	of 70

Accuray to Acquire Morphormics, Inc. Acquisition Allows Accuray to Provide Leading-Edge Image Processing Software and Further its Mission to Deliver Personalized Treatment Solutions SUNNYVALE, Calif., July 16, 2012 /PRNewswire via COMTEX/ -- Accuray Incorporated (ARAY), the premier radiation oncology company, announced today that they have signed a definitive agreement to acquire Morphormics, Inc., a privately held company founded by University of North Carolina at Chapel Hill faculty members based on their research in autosegmentation of medical images. Morphormics develops medical imaging software systems that automatically recognize and extract anatomical structures from medical images. The agreement provides that Accuray will pay approximately $5.7 million. In 2008, Accuray began licensing Morphormics' autocontouring technology, which automatically identifies and draws the boundaries of the prostate and surrounding critical structures. This enables the treatment planning software to focus the radiation dose on the prostate and minimize the delivery of radiation to surrounding critical structures. With the acquisition of Morphormics, Accuray plans to extend autocontouring capabilities for both the CyberKnife Robotic Radiosurgery System and the TomoTherapy System to improve disease specific workflows. "Since our licensing agreement with Morphormics began, we have seen firsthand the benefits the company's technology provides clinicians in improving efficiency, especially in the treatment of prostate cancer, and its potential to improve patient outcomes," said Euan S. Thomson, Ph.D., Accuray president and chief executive officer. "The acquisition of Morphormics will expand Accuray's IP portfolio, reduce our licensing expenses and strengthen our engineering team with top talent from the University of North Carolina at Chapel Hill. This strategic acquisition is another important step toward providing leading-edge treatment solutions personalized for each cancer patient." "This is an exciting opportunity for our company that will bring the benefits of our technology to more patients," said Edward Chaney, Ph.D., co-founder of Morphormics and professor of Radiation Oncology and Biomedical Engineering at the University of North Carolina at Chapel Hill. "Accuray's acquisition confirms the value our technology offers in its ability to dramatically increase efficiency and accuracy in the delivery of image-guided medical treatment. We look forward to joining the Accuray team and further advancing innovation in this area." About Accuray Accuray Incorporated (ARAY), based in Sunnyvale, Calif., is the premier radiation oncology company that develops, manufactures and sells personalized innovative treatment solutions that set the standard of care, with the aim of helping patients live longer, better lives. The Company's leading edge technologies - the CyberKnife and TomoTherapy Systems - are designed to deliver radiosurgery, stereotactic body radiation therapy, intensity modulated radiation therapy, image guided radiation therapy, and adaptive radiation therapy. To date 635 systems have been installed in leading hospitals around the world. For more information, please visit accuray.com.

Share	Recommend \| Keep \| Reply \| Mark as Last Read

From: Savant	7/31/2012 12:20:45 PM
	of 70

Accuray Incorporated to Report Financial Results for Fourth Quarter and Fiscal Year 2012 SUNNYVALE, Calif., July 31, 2012 /PRNewswire via COMTEX/ -- Accuray Incorporated (ARAY), the premier radiation oncology company, today announced that it will report results for its fourth quarter and fiscal year 2012, ended June 30, 2012 on Thursday, September 6, 2012 after the market closes. A conference call to review the results will begin at 2:00 p.m. PDT/5:00 p.m. EDT and will be hosted by Euan S. Thomson, Ph.D., president and chief executive officer and Derek Bertocci, senior vice president and chief financial officer. The conference call dial-in numbers are 1-800-295-4740 (USA) or 1-617-614-3925 (International), Conference ID: 89497327. In addition, a dial-up replay of the conference call will be available beginning September 6, 2012 at 5:00 p.m. PDT/8:00 p.m. EDT and ending on September 13, 2012. The replay telephone number is 1-888-286-8010 (USA) or 1-617-801-6888 (International), Conference ID: 79000863. A live webcast of the call will also be available from the Investor Relations section of the corporate website at accuray.com A webcast replay can be accessed on the corporate website beginning Thursday, September 6, 2012 at approximately 5:00 p.m. PDT/8:00 p.m. EDT. The replay will remain available until Accuray announces its results for the first quarter of fiscal 2013, ending September 30, 2012. About Accuray Accuray Incorporated (ARAY), based in Sunnyvale, Calif., is the premier radiation oncology company that develops, manufactures and sells personalized innovative treatment solutions that set the standard of care, with the aim of helping patients live longer, better lives. The Company's leading edge technologies - the CyberKnife and TomoTherapy Systems - are designed to deliver radiosurgery, stereotactic body radiation therapy, intensity modulated radiation therapy, image guided radiation therapy, and adaptive radiation therapy. To date, more than 635 systems have been installed in leading hospitals around the world. For more information, please visit accuray.com.

Share	Recommend \| Keep \| Reply \| Mark as Last Read

From: Savant	7/31/2012 1:27:20 PM
	of 70

Clinical Research on Accuray's CyberKnife? and TomoTherapy? Systems to Be Presented at Key Industry Event for Medical Physicists Accuray to Host an Educational Symposium Highlighting Enhanced Capabilities of Its CyberKnife and TomoTherapy Treatment Systems SUNNYVALE, Calif., July 29, 2012 /PRNewswire via COMTEX/ -- Accuray Incorporated (ARAY), the premier radiation oncology company, announced today that more than 70 studies on the clinical use of the CyberKnife Robotic Radiosurgery? System and the TomoTherapy? System will be presented at the 54th Annual Meeting of the American Association of Physicists in Medicine (AAPM) taking place in Charlotte, N.C. July 29 - August 2, 2012. The Annual AAPM Meeting usually draws about 4,000 attendees. Studies from leading centers will showcase both the CyberKnife System and the TomoTherapy System. The presentations continue to validate Accuray's standard-setting treatment planning and delivery techniques, accurate patient setup and intrafraction motion tracking, as well as quality assurance practices for the industry's premier, fully-integrated radiosurgery and intensity-modulated radiotherapy platforms. Of note are studies that emphasize the benefits of each technology in demanding clinical situations. Key examples are the TomoTherapy System's unmatched ability to provide organ sparing and dose homogeneity in hippocampal-avoidance whole brain radiotherapy and the CyberKnife System's ability to maintain continual tracking accuracy during treatment of liver tumors undergoing a large degree of respiratory motion. Accuray will also host a symposium on Monday, July 30, 2012 from 12:30 p.m. EDT - 1:30 p.m. EDT at The Westin Charlotte Hotel. The session will focus on Accuray's new VoLO(TM) technology for the TomoTherapy System, a treatment planning platform that leverages advanced parallel processing technology and a new dose calculation algorithm to increase clinical efficiency, throughput and flexibility in developing even the most complex treatment plans. In addition, the symposium will highlight TomoTherapy's new Dose Control System, improving system stability during and between treatments. "Medical physicists play a vital role in the radiation therapy field, ensuring patient safety and treatment quality, two areas to which Accuray is strongly dedicated," said Euan S. Thomson, Ph.D., Accuray president and chief executive officer."We are pleased by the quantity and quality of clinical research being presented. This work adds to the growing body of scientific evidence validating the safe and effective use of our products for an expanding range of clinical indications." Accuray will be exhibiting at booth #909. Presenters include Robert Staton, Medical Physicist, MD Anderson Orlando who will be presenting on his experience with the TomoTherapy Dose Control System and Kenneth Ruchala, Ph.D., Accuray Incorporated who will be presenting information on the Non-Voxel Broad Beam algorithm for a GPU-based dose calculator. Additionally, Accuray will host demonstrations of its VoLO technology for the TomoTherapy System at the booth. The TomoTherapy System is a fully integrated 3D image guided intensity modulated radiation therapy system that provides patients with the most accurate, personalized cancer care. The technology uses daily computed tomography (CT) imaging to identify the exact position of the tumor on each day of treatment, enabling clinicians to customize treatment for each patient, minimize radiation exposure to healthy tissue and reduce side effects. The TomoTherapy System uses a radiation beam that continually rotates in 360 degree arcs about the patient, meaning that treatments can be delivered continuously to the tumor from every angle. The CyberKnife System is the first and only robotic radiosurgery system that provides a pain-free, non-invasive treatment option for patients who are looking for an alternative to surgery or who have an inoperable or surgically complex tumor. CyberKnife treatment is typically completed in just one to five days, instead of the 40 or more treatment sessions typically required with conventional radiation therapy. The CyberKnife System offers unique capabilities that automatically account for the natural motion of the tumor throughout treatment. The ability to manage motion in real time helps ensure that radiation is delivered only to the tumor while sparing healthy tissue and critical structures. About AccurayAccuray Incorporated (ARAY), based in Sunnyvale, Calif., is the premier radiation oncology company that develops, manufactures and sells personalized innovative treatment solutions that set the standard of care, with the aim of helping patients live longer, better lives. The Company's leading edge technologies - the CyberKnife and TomoTherapy Systems - are designed to deliver radiosurgery, stereotactic body radiation therapy, intensity modulated radiation therapy, image guided radiation therapy, and adaptive radiation therapy. To date 635 systems have been installed in leading hospitals around the world. For more information, please visit accuray.com. Safe Harbor Statement Statements made in this press release that are not statements of historical fact are forward-looking statements and are subject to the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements in this press release relate, but are not limited, to reduced radiation exposure, accuracy, clinical efficiency, clinical applications, and clinical benefits. Forward-looking statements are subject to risks and uncertainties that could cause actual results to differ materially from expectations, including risks detailed from time to time under the heading "Risk Factors" in the Company's report on Form 10-K for fiscal year 2011, and its reports on Form 10-Q for the first, second and third quarters of fiscal 2012. Forward-looking statements speak only as of the date the statements are made and are based on information available to the Company at the time those statements are made and/or management's good faith belief as of that time with respect to future events. The Company assumes no obligation to update forward-looking statements to reflect actual performance or results, changes in assumptions or changes in other factors affecting forward-looking information, except to the extent required by applicable securities laws. Accordingly, investors should not place undue reliance on any forward-looking statements.

Share	Recommend \| Keep \| Reply \| Mark as Last Read

From: richardred	10/18/2012 9:44:26 AM
	of 70

Accuray to Announce Significant Product News at ASTRO2012 ASTRO Meeting Provides Multiple Opportunities to Learn about Accuray's Leading Radiation Oncology Treatment Solutions Press Release: Accuray Incorporated – 38 minutes ago SUNNYVALE, Calif., Oct. 18, 2012 /PRNewswire/ -- Accuray Incorporated ( ARAY), the premier radiation oncology company, will announce significant product news at the 54th Annual American Society for Radiation Oncology (ASTRO) Meeting taking place at the Boston Convention Center. Accuray will unveil two advanced technology platforms designed to deliver unparalleled, precise and personalized treatment to the full range of cancer patients. There will be many opportunities to learn about Accuray's advanced radiation oncology treatment solutions at the 2012 ASTRO annual meeting, including: New product unveiling: Join Accuray's President and Chief Executive Officer Joshua H. Levine, when he presents the company's two advanced technology platforms on Sunday, October 28 at 11:00 a.m. ET in the Accuray booth #7101. The presentation will reveal the results of Accuray's investment in the development of these next generation technologies, which will be on display in the booth. The presentation will review their clinical capabilities and the value they bring to both patients and physicians within the radiation oncology community. Clinical research presentations: Accuray's CyberKnife® Robotic Radiosurgery and TomoTherapy® Radiation Therapy Systems will be the subject of many clinical presentations and posters. A paper session on hypofractionated treatment of prostate cancer that will include three talks on CyberKnife prostate SBRT is scheduled for Wednesday, October 30 from 1:30-3:00 p.m. All presentation dates, times and locations for clinical presentations on the CyberKnife and TomoTherapy Systems can be found here (http://www.accurayboston2012.com/Booths.aspx). Industry expert theater: Accuray will host a symposium at the ASTRO Industry Expert Theater titled, "New Clinical Advancements in the Field of Radiosurgery and Radiation Therapy," presented by Mary Ann Stevenson, M.D., Ph.D., Radiation Oncologist and Chief, Department of Radiation Oncology at Beth Israel Deaconess Medical Center and PD Dr. Florian Sterzing, M.D., Consultant Radiation Oncologist at University Clinic of Heidelberg on Monday, October 29, 2012 from 12:30 p.m. – 1:30 p.m. ET in the Exhibit Hall. Lunch will be served. In-booth presentations and product demonstrations: At the top of each hour while the exhibit hall is open, Accuray will offer in-booth presentations and product demonstrations on the clinical advantages of both the TomoTherapy and CyberKnife Systems. The exhibit hall will be open Sunday, October 28 – Tuesday, October 30 from 10:00 a.m. – 5:00 p.m. ET each day. For those interested in registering for product demonstrations in advance please visit: accurayboston2012.com meeting: Accuray's management will host a breakfast meeting for institutional investors and research analysts on Monday, October 29 from 7:30 a.m. to 9:30 a.m. E.D.T. on Monday, October 29 at the Renaissance Boston Waterfront Hotel, 606 Congress Street Boston, in the Pacific Ballroom, Salon A-C. The presentation will provide a review of Accuray's new technology platforms that will be introduced at ASTRO. A live webcast of the presentation will be available online from the investor relations section of the company website at www.accuray.com/investors. Investors and analysts planning to attend this meeting are asked to register no later than Friday, October 19 from our event website: cvent.com ASTRO Activities: American Society of Radiologic Technologists (ASRT) Participation, Titanium sponsor: Accuray will be located at table one on the fourth floor atrium area of the Boston Marriott Copley Place, Boston MA. The Society for Radiation Oncology Administrators (SROA) participation, Platinum sponsor: Accuray will be located at table four found on the first floor the Hyatt Regency, Cambridge, MA. Additionally, on Sunday, October 28 at 11:45 a.m. ET Accuray will be presenting on our latest product offerings at the SROA table. Follow the Accuray Twitter handle, @Accuray, for real-time updates from the ASTRO show floor. To schedule a briefing with an Accuray executive, please contact Rebecca Phillips, rphillips@accuray.com or +1 (408) 242-3831. About Accuray Accuray Incorporated ( ARAY), based in Sunnyvale, Calif., is the premier radiation oncology company that develops, manufactures and sells personalized innovative treatment solutions that set the standard of care, with the aim of helping patients live longer, better lives. The Company's leading edge treatment solutions – the CyberKnife and TomoTherapy Systems – are designed to deliver radiosurgery, stereotactic body radiation therapy, intensity modulated radiation therapy, image guided radiation therapy, and adaptive radiation therapy. To date 642 systems have been installed in leading hospitals around the world. For more information, please visit www.accuray.com. Safe Harbor Statement Statements made in this press release that are not statements of historical fact are forward-looking statements and are subject to the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements in this press release relate, but are not limited, significance of product releases, range of cancer patients, clinical capabilities of products, clinical research, clinical advantages, quality of treatments, and the Company's leadership position in radiation oncology innovation. Forward-looking statements are subject to risks and uncertainties that could cause actual results to differ materially from expectations, including risks detailed from time to time under the heading "Risk Factors" in the company's report on Form 10-K filed on September 10, 2012. Forward-looking statements speak only as of the date the statements are made and are based on information available to the Company at the time those statements are made and/or management's good faith belief as of that time with respect to future events. The Company assumes no obligation to update forward-looking statements to reflect actual performance or results, changes in assumptions or changes in other factors affecting forward-looking information, except to the extent required by applicable securities laws. Accordingly, investors should not place undue reliance on any forward-looking statements. finance.yahoo.com

Share	Recommend \| Keep \| Reply \| Mark as Last Read

Copyright/IP Policy

Copyright © 1995-2013 Knight Sac Media. All rights reserved.